Skip to main content

Table 1 The patients’ characteristics

From: Diode laser transscleral cyclophotocoagulation followed by phacotrabeculectomy on medically unresponsive acute primary angle closure eyes: the long-term result

Case Eye affected Durations (days) Medical treatment before cyclophotocoagulation Presenting IOP (mmHg) VA (LogMAR)
1 Left 7 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID 43.2 HM
2 Left 11 1% pilocarpine Q2H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD 43.6 1.0
3 Right 7 1% pilocarpine QID, 2% carteolol Q12H, 0.2% Brimonidine BID, intravenous 20% mannitol 400 ml QD 45.0 2.0
4 Left 6 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 50 mg BID, intravenous 20% mannitol 400 ml Q12H 48.6 0.9
5 Right 23 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml Q12H 54.2 HM
6 Left 20 1% pilocarpine TID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 50 mg BID 58.7 HM
7 Left 15 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID 44.8 FC
8 Right 17 1% pilocarpine QID, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 250 ml QD 47.0 1.0
9 Right 12 1% pilocarpine QID, 2% carteolol Q12H, 1% Brinzolamide TID, 0.2% Brimonidine BID, oral Methazolamide 25 mg BID, intravenous 20% mannitol 400 ml QD 50.0 FC
  1. IOP: intraocular pressure, VA: vision acuity, HM: hand movement, FC: finger counting.
  2. Case 1, 6 and 7 were not administered mannitol for systemic disease (such as renal dysfunction, cardiac insufficiency, etc), case 2 and 8 were not administered beta-blocker for atrioventricular block, case 1 and 3 were not administered carbonic anhydrase inhibitors for medication allergy.